These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 14560766)
1. Dosage individualization of erythropoietin using a profile-dependent support vector regression. Martín-Guerrero JD; Camps-Valls G; Soria-Olivas E; Serrano-López AJ; Pérez-Ruixo JJ; Jiménez-Torres NV IEEE Trans Biomed Eng; 2003 Oct; 50(10):1136-42. PubMed ID: 14560766 [TBL] [Abstract][Full Text] [Related]
2. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. Li H; Wang SX Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498 [TBL] [Abstract][Full Text] [Related]
3. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial. Lee YK; Koo JR; Kim JK; Park II; Joo MH; Yoon JW; Noh JW; Vaziri ND Am J Kidney Dis; 2009 May; 53(5):815-22. PubMed ID: 19324483 [TBL] [Abstract][Full Text] [Related]
4. The effect of high-flux hemodialysis on renal anemia. Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038 [TBL] [Abstract][Full Text] [Related]
5. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549 [TBL] [Abstract][Full Text] [Related]
6. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416 [TBL] [Abstract][Full Text] [Related]
7. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC). Pizzarelli F; David S; Sala P; Icardi A; Casani A Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298 [TBL] [Abstract][Full Text] [Related]
8. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. Saudan P; Halabi G; Perneger T; Wasserfallen JB; Wauters JP; Martin PY; J Nephrol; 2006; 19(1):91-6. PubMed ID: 16523432 [TBL] [Abstract][Full Text] [Related]
10. Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness? Gabutti L; Lötscher N; Bianda J; Marone C; Mombelli G; Burnier M BMC Nephrol; 2006 Sep; 7():13. PubMed ID: 16981983 [TBL] [Abstract][Full Text] [Related]
11. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC; Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340 [TBL] [Abstract][Full Text] [Related]
12. Challenging the validity of the EPO index. Kaysen GA; Müller HG; Ding J; Chertow GM Am J Kidney Dis; 2006 Jan; 47(1):166. PubMed ID: 16377397 [TBL] [Abstract][Full Text] [Related]
13. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148 [TBL] [Abstract][Full Text] [Related]
14. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3. Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544 [TBL] [Abstract][Full Text] [Related]
15. Do hemodialysis patients need higher doses of erythropoietin if given intravenously rather than subcutaneously? McMahon LP Nat Clin Pract Nephrol; 2006 May; 2(5):246-7. PubMed ID: 16932434 [No Abstract] [Full Text] [Related]